CF
ARQT icon

Cantor Fitzgerald’s Arcutis Biotherapeutics ARQT Stock Holding History

Cantor Fitzgerald’s Portfolio ARQT Stock Details ARQT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-10,114
Closed -$32.7K – 277
2023
Q4 		$32.7K Buy
+10,114
New +$27.5K 0.01% 177
2023
Q3 		– Sell
-56,903
Closed -$542K – 558
2023
Q2 		$542K Buy
+56,903
New +$632K 0.01% 360

Other funds holding ARQT

Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
GGHC
Gilder Gagnon Howe & Co New York $8.34B AUM 46.58% 1-Year Est. Return

Cantor Fitzgerald's ARQT Position: Q1 2024 in Review

Cantor Fitzgerald sold out of Arcutis Biotherapeutics (ARQT) in Q1 2024, closing a stake of 10,114 shares — an estimated $32.7K sold.

Cantor Fitzgerald first reported a position in ARQT in Q2 2023 and held it in 2 quarters. The position peaked at $542K in Q2 2023. 168 funds tracked by Wall St. Rank hold ARQT as of Q1 2024.

  • Cantor Fitzgerald reported no remaining Arcutis Biotherapeutics position as of Q1 2024 after selling out during the quarter.
  • Cantor Fitzgerald sold 10,114 Arcutis Biotherapeutics shares in Q1 2024, an estimated $32.7K.
  • Cantor Fitzgerald first reported a position in Arcutis Biotherapeutics in Q2 2023 and held it in 2 quarters.
  • Cantor Fitzgerald's Arcutis Biotherapeutics position peaked at $542K in Q2 2023.
  • 168 funds tracked by Wall St. Rank held Arcutis Biotherapeutics as of Q1 2024.

Based on Cantor Fitzgerald's 13F filing for Q1 2024, filed 15 May 2024.